Chardan Capital Markets Recent News
Clovis Shares Reiterated As A Sell Following 10% Rally
Chardan Analyst Suggests An AveXis-Ionis Pair Trade
Social Reality Wins A Buy Rating, $9 Price Target From Chardan
Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April
Despite Guidance Miss, Teladoc Still Attractive
5 Key Takeaways In Regeneron's Praluent Suit, Steps Forward
The Medicines Co. Is A Top Pick For 2017
Reasons To Stay Bullish On Alnylam In The New Year
For Arbutus' Hepatitis B Treatment, 'Liver Safety Risk Overwhelms Promising Efficacy'
Chardan Upgrades Regeneron; Cites Fovista Failure, Stock's Recent Underperformance
Chardan Downgrades Ophthotech As Fovista Fails Phase III Trials For Wet AMD
4 Possible Catalysts On Eyegate's Horizon
Chardan: Watch Wearable Maker Vuzix Into CES
Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space
WageWorks Shares Could Rise 16% Over Next Year
Arrowhead Pharma Downgraded Following EX-1 RNAi Program Discontinuations
Amicus Therapeutics: Here's The Good News
Teladoc Shares Could Rise 40% Over The Next Year
Chardan Recommends Selling Clovis Oncology
Novartis A Buy At Chardan
3 Turnaround Stories Getting Love From Sell-Side Analysts
Chardan Analyst Believe iPass' Turnaround Strategy Is Working
Weak Competition, Favorable Regulatory Environment Among Tailwinds For Sunworks